Digestive Diseases and Sciences

, Volume 58, Issue 4, pp 1149–1156 | Cite as

The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease

  • Ming Valerie Lin
  • Wojciech Blonski
  • Anna M. Buchner
  • K. Rajender Reddy
  • Gary R. LichtensteinEmail author
Original Article



The immunosuppressive potential of anti-tumor necrosis factor (TNF) in exacerbating chronic hepatitis C virus (HCV) infection has been a major concern. We aim to critically analyze the impact of anti-TNF on the course of chronic HCV infection in patients with concurrent inflammatory bowel disease (IBD) and HCV infection.

Materials and Methods

Patients with diagnosis of IBD and HCV were identified retrospectively through the University of Pennsylvania Health System electronic database. Data assessed included demographics, duration of IBD and HCV infection, HCV RNA levels, HCV genotype, liver histology, hepatic biochemical tests (HBT) and IBD disease activity index.


A total of 4,274 IBD and 3,523 HCV patients were identified from 10/1998 to 05/2010. Thirty-seven patients had concurrent HCV infection and IBD, of which 23 patients were eligible (61 % CD; 39 % UC). Five patients (22 %) received anti-TNF therapy (infliximab). Two patients received pegylated interferon and ribavirin (both were non-responders). Overall, three patients had clinical remission and one patient had clinical response to infliximab. When compared to baseline, one patient had HBT improvement, three patients remained stable and one patient had HBT elevation, which was likely due to progressive liver disease in view of HIV co-infection.


This represents the first critical analysis assessing the impact of anti-TNF therapy on the course of chronic HCV in IBD patients. Concurrent HCV infection in IBD patients is uncommon. Treatment of IBD with infliximab in HCV patients did not result in flares in hepatic biochemical tests while there was an improvement in the IBD disease activity score.


Inflammatory bowel disease Ulcerative colitis Crohn’s disease Hepatitis C virus infection Anti-TNF Infliximab 


Conflict of interest

Dr. Gary R. Lichtenstein has served as a consultant and performed research with Alaven, Jansen Orthobiotech, Proctor and Gamble, Warner Chilcotte, UCB, Prometheus Laboratories, Inc, Salix Pharmaceuticals, Shire Pharmaceuticals, Santarus, Ferring. He has served as a consultant to Abbott Corporation, Elan, Meda, Millenium, Ono Pharmaceuticals. Pfizer, Schering Plough, Wyeth. He has done research with Bristol-Myers Squibb.


  1. 1.
    Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.PubMedCrossRefGoogle Scholar
  2. 2.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.PubMedCrossRefGoogle Scholar
  3. 3.
    Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis. 2004;10:657–660.PubMedCrossRefGoogle Scholar
  4. 4.
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.PubMedCrossRefGoogle Scholar
  5. 5.
    Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171.PubMedCrossRefGoogle Scholar
  6. 6.
    Kallinowski B, Haseroth K, Marinos G, et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998;111:269–277.PubMedCrossRefGoogle Scholar
  7. 7.
    Kishihara Y, Hayashi J, Yoshimura E, et al. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 1996;41:315–321.PubMedCrossRefGoogle Scholar
  8. 8.
    Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487–2494.PubMedCrossRefGoogle Scholar
  9. 9.
    Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 1996;16:390–399.PubMedGoogle Scholar
  10. 10.
    Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 1996;23:210–217.PubMedGoogle Scholar
  11. 11.
    Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63:ii18–ii24.PubMedCrossRefGoogle Scholar
  12. 12.
    Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–322.PubMedCrossRefGoogle Scholar
  13. 13.
    Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.PubMedCrossRefGoogle Scholar
  14. 14.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.PubMedCrossRefGoogle Scholar
  15. 15.
    Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.PubMedCrossRefGoogle Scholar
  16. 16.
    Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey–Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.PubMedCrossRefGoogle Scholar
  17. 17.
    Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.PubMedCrossRefGoogle Scholar
  18. 18.
    Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn’s disease. Am J Gastroenterol. 2007;102:1333–1334.PubMedCrossRefGoogle Scholar
  19. 19.
    Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13:191–192.PubMedCrossRefGoogle Scholar
  20. 20.
    Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003;98:504–505.PubMedCrossRefGoogle Scholar
  21. 21.
    Biancone L, Del Vecchio Blanco G, Pallone F, et al. Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology. 2002;122:593–594.PubMedCrossRefGoogle Scholar
  22. 22.
    Katsanos KH, Tsianos VE, Zois CD, et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis. 2010;4:450–465.PubMedCrossRefGoogle Scholar
  23. 23.
    Chevaux JB, Bigard MA, Bensenane M, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009;33:1082–1093.PubMedCrossRefGoogle Scholar
  24. 24.
    Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull. 2009;92:61–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Horn TL, Reynolds J, de Villiers W, et al. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci. 2009;54:1171–1177.PubMedCrossRefGoogle Scholar
  27. 27.
    Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis. 2001;7:287–294.PubMedCrossRefGoogle Scholar
  28. 28.
    Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340–1346.PubMedCrossRefGoogle Scholar
  29. 29.
    Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009;104:57–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Chevaux JB, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916–924.PubMedCrossRefGoogle Scholar
  31. 31.
    Alderson JW, Van Dinter TG Jr, Opatowsky MJ, et al. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literature. MedGenMed. 2005;7:7.PubMedGoogle Scholar
  32. 32.
    Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944–1949.PubMedGoogle Scholar
  33. 33.
    Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford). 2007;46:97–99.CrossRefGoogle Scholar
  34. 34.
    Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–1082.PubMedCrossRefGoogle Scholar
  35. 35.
    Longo F, Hebuterne X, Tran A, et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24:77–81.PubMedGoogle Scholar
  36. 36.
    Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology. 1996;226:176–182.PubMedCrossRefGoogle Scholar
  37. 37.
    Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem. 1998;273:2256–2259.PubMedCrossRefGoogle Scholar
  38. 38.
    Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006;26:1029–1039.PubMedCrossRefGoogle Scholar
  39. 39.
    Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264–274.PubMedGoogle Scholar
  40. 40.
    Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994;179:841–848.PubMedCrossRefGoogle Scholar
  41. 41.
    Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Ming Valerie Lin
    • 1
  • Wojciech Blonski
    • 2
    • 3
  • Anna M. Buchner
    • 2
  • K. Rajender Reddy
    • 2
  • Gary R. Lichtenstein
    • 2
    • 4
    Email author
  1. 1.Division of Digestive DiseaseUniversity of CincinnatiCincinnatiUSA
  2. 2.Division of GastroenterologyUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of GastroenterologyMedical UniversityWrocławPoland
  4. 4.Gastroenterology DivisionUniversity of Pennsylvania School of Medicine, Hospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations